Cellectar Biosciences (CLRB) EPS (Diluted) Growth (5y) (2020 - 2026)
Cellectar Biosciences (CLRB) EPS (Diluted) Growth (5y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.19% |
| Dec 31, 2025 | 47.75% |
| Sep 30, 2025 | 49.11% |
| Jun 30, 2025 | 66.28% |
| Mar 31, 2025 | 66.61% |
| Dec 31, 2024 | 35.11% |
| Sep 30, 2024 | 59.54% |
| Jun 30, 2024 | 58.84% |
| Mar 31, 2024 | 58.82% |
| Dec 31, 2023 | 48.41% |
| Sep 30, 2023 | 54.48% |
| Jun 30, 2023 | 52.38% |
| Mar 31, 2023 | 51.32% |
| Dec 31, 2022 | 24.37% |
| Sep 30, 2022 | 46.10% |
| Jun 30, 2022 | 46.11% |
| Mar 31, 2022 | 46.73% |
| Dec 31, 2021 | 67.21% |
| Sep 30, 2021 | 67.20% |
| Jun 30, 2021 | 65.71% |